As of Jun 26
| -0.40 / -3.83%|
The 6 analysts offering 12-month price forecasts for Amicus Therapeutics Inc have a median target of 12.25, with a high estimate of 18.00 and a low estimate of 10.00. The median estimate represents a +22.01% increase from the last price of 10.04.
The current consensus among 6 polled investment analysts is to Buy stock in Amicus Therapeutics Inc. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.